title: [Invasive pneumococcal disease in children younger than 5 years in Navarra, Spain (2000-2005). Impact of the conjugate vaccine].
abstract: OBJECTIVE
  The 7-valent pneumococcal conjugate vaccine (PCV7) has been commercialized in Spain since June 2001. We aim to evaluate the impact of this vaccine in the incidence of invasive pneumococcal disease (IPD) in Navarre.
  
  
  METHODS
  The laboratories of microbiology of Navarre declare all the isolations of Streptococcus pneumoniae in samples of normally sterile corporal fluids. We analyzed the incidence of IPD in children younger than 5 years between weeks 41 of 2000 and 40 of 2005.
  
  
  RESULTS
  The doses of PCV7 sold up to 2005 would provide a cover of 27% in children younger than 5 years, having assumed 4 dose schedules. In the 5 seasons, 103 cases of IPD were diagnosed. From the 2 first seasons (2000-2002) to the last one (2004-2005) a reduction of 69% in the incidence rate of IPD caused by vaccine serotypes was observed (from 33 to 10 cases by 100,000 children under 5 years; p = 0.003). Between those same periods the incidence of IPD caused by non-vaccine serotypes increased a 36% (from 42 to 57 by 100,000; p = 0.405). The global incidence of IPD diminished a 12% (from 77 to 67 by 100,000; p = 0.689). The percentage of cases that had received PCV7 increased until 45% in season 2004-2005 (p < 0.001). The meningitis and bacteraemic pneumonias supposed 42% of the IPD, without significant changes during the period (p = 0.442).
  
  
  CONCLUSIONS
  Since the PCV7 was marketed the pattern of serotypes has changed, but the expected reduction in the total IPD incidence has not been achieved.
authors.affiliation: Instituto de Salud Pública de Navarra, Pamplona, Navarra, España. abarricg@cfnavarra.es
authors.forename: Aurelio
authors.initials: A
authors.lastname: Barricarte
authors.forename: Alberto
authors.initials: A
authors.lastname: Gil-Setas
authors.forename: Luis
authors.initials: L
authors.lastname: Torroba
authors.forename: Jesús
authors.initials: J
authors.lastname: Castilla
authors.forename: Alba
authors.initials: A
authors.lastname: Petit
authors.forename: Isabel
authors.initials: I
authors.lastname: Polo
authors.forename: Maite
authors.initials: M
authors.lastname: Arriazu
authors.forename: Fátima
authors.initials: F
authors.lastname: Irisarri
authors.forename: Manuel
authors.initials: M
authors.lastname: García Cenoz
mesh_terms: D002675:Child, Preschool; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D015994:Incidence; D007223:Infant; D022401:Meningococcal Vaccines; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines; D013030:Spain / Q000453:epidemiology
chemical_list: D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines